1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. GLOBAL CANCER IMMUNOTHERAPY MARKET BY TYPE
5.1. Introduction
5.2. Monoclonal antibodies (MABs)
5.3. Checkpoint Inhibitors
5.4. Cytokines
5.5. Cancer vaccines
5.6. Adoptive Cell Transfer
6. GLOBAL CANCER IMMUNOTHERAPY MARKET BY APPLICATION
6.1. Introduction
6.2. Melanoma
6.3. Lung Cancer
6.4. Leukemias
6.5. Bladder Cancer
6.6. Breast Cancer
6.7. Colorectal Cancer
6.8. Others
7. GLOBAL CANCER IMMUNOTHERAPY MARKET BY END USER
7.1. Introduction
7.2. Hospitals and Clinics
7.3. Cancer Research Centers
8. GLOBAL CANCER IMMUNOTHERAPY MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. United States
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. Italy
8.4.4. United Kingdom
8.4.5. Others
8.5. Middle East & Africa
8.5.1. Israel
8.5.2. Saudi Arabia
8.5.3. UAE
8.5.4. Others
8.6. Asia Pacific
8.6.1. Japan
8.6.2. China
8.6.3. India
8.6.4. Australia
8.6.5. South Korea
8.6.6. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Servier
10.2. Sanofi
10.3. Xencor
10.4. Pfizer Inc.
10.5. Cellectis SA
10.6. CytomX Therapeutics, Inc.
10.7. Bristol-Myers Squibb Company
10.8. Nektar
10.9. Eisai Co., Ltd.
10.10. Merck & Co., Inc.
10.11. F. Hoffmann-La Roche Ltd.
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES